Menu
Cart 0
Becker Muscular Dystrophy Pipeline Analysis 2018 (Q1)

Becker Muscular Dystrophy Pipeline Analysis 2018 (Q1) – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments

  • $2,400.00
  • Publishing Date: February 2018
  • Format: PDF
Sample Request

Becker Muscular Dystrophy Pipeline Analysis 2018 – Focusing on Clinical Trials and Results, Drug Profiling, Patents, Collaborations, and Other Developments.

Becker Muscular Dystrophy (BMD) Pipeline Analysis report covers 6 drugs currently in different phases of development. Becker muscular dystrophy is an X-linked recessive genetic disorder characterized by progressive weakness and wasting of the skeletal and cardiac muscles and is caused by is caused by a mutation in the DMD gene. This mutation that lead to a damaged "version" of dystrophin. Mutations that lead to an abnormal "version" of dystrophin that allow it to keep some of its function usually cause BMD. Muscle weakness often affects the legs and pelvis and gets worse with time leading to difficulty in walking, frequent falls and loss of muscle mass. It also affects cardiac muscles which may lead to cardiomyopathy. Laboratory tests such as Electromyography, Muscle biopsy or genetic testing and Creatine phosphokinase (CPK) are performed to diagnose the disease.

The report provides BMD treatment drugs by company, phases of development including products in early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.

Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.

Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining faster and efficient understanding of the market.

Major industry players profiled as part of the report are Italfarmaco S.p.A and Cardero Therapeutics Inc. among others.

Scope:

  • By Company
  • By Phase
  • By Molecule Type
  • By Region
  • By Route of Administration
1. Introduction
1.1. Research Methodology
1.2. Research Scope
1.2.1. Analysis by Company
1.2.2. Analysis by Phase
1.2.3. By Molecule Type
1.2.4. By region
2. Disease Overview
2.1.1. Introduction
2.1.2. Classification
2.1.3. Symptoms
2.1.4. Causes
2.1.5. Diagnoses
2.1.6. Treatment
2.1.7. Epidemiology
3. Executive Summary
4. Market Dynamics
4.1. Drivers
4.2. Restraints
4.3. Opportunities
5. Pipeline Analysis/Outlook
5.1. Analysis by Company
5.2. Analysis by Phase
5.2.1. Phase of Development
5.2.1.1. Introduction
5.2.1.1.1. Drug Profiling
• Drug Name
• Generic Name
• Synonyms
• Company
• Collaborator
• Route of administration
• Target
• Mechanism of Action
• Technology
• Molecule type
• CAS Number
• Weight
• Chemical Formula
• IUPAC name
• ATC code
5.2.1.1.2. Strategic Developments
5.2.1.1.3. Clinical trials
5.2.1.1.4. Clinical trial results
5.2.1.1.5. Patents
5.2.1.1.6. Technology
5.2.2. Comparative Analysis for Trials by Phase (Pie, Bar graph)
5.3. By Molecule type
5.4. Analysis by Region
6. Company profiling
6.1. Italfarmaco S.p.A
6.1.1. Introduction
6.1.2. Financials
6.1.3. Products and Services
6.1.4. SWOT
6.2. Cardero Therapeutics Inc.
6.2.1. Introduction
6.2.2. Financials
6.2.3. Products and Services
6.2.4. SWOT
6.3. Milo Biotechnology
6.3.1. Introduction
6.3.2. Financials
6.3.3. Products and Services
6.3.4. SWOT
6.4. Tivorsan Pharmaceuticals
6.4.1. Introduction
6.4.2. Financials
6.4.3. Products and Services
6.4.4. SWOT
6.5. Catabasis Pharmaceutical
6.5.1. Introduction
6.5.2. Financials
6.5.3. Products and Services
6.5.4. SWOT
6.6. ReveraGen BioPharma, Inc.
6.6.1. Introduction
6.6.2. Financials
6.6.3. Products and Services
6.6.4. SWOT
6.7. ixte Biotechnology Holdings, Inc.
6.7.1. Introduction
6.7.2. Financials
6.7.3. Products and Services
6.7.4. SWOT

6.8. Pharming Group NV
6.8.1. Introduction
6.8.2. Financials
6.8.3. Products and Services
6.8.4. SWOT
6.9. Adienne Pharma and Biotech
6.9.1. Introduction
6.9.2. Financials
6.9.3. Products and Services
6.9.4. SWOT
6.10. Greenovation Biopharmaceuticals
6.10.1. Introduction
6.10.2. Financials
6.10.3. Products and Services
6.10.4. SWOT

Related Reports
Back to the top